Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...

The COMPANION study will test a cognitive behavioural therapy-based DTx called Almee (formerly VP04) – developed in partnership with digital health company Alex Therapeutics – to see if it can ...

IPF is an irreversible progressive condition ... Owlstone is based in Cambridge and is also working on a cancer breathalyser test. Billy Boyle, co-founder and CEO at Owlstone Medical, said ...

IPF is rapidly progressive and causes scarring in the lungs, making it difficult to breathe. Approximately 50% of patients die within three years of diagnosis, and current treatments can only slow ...

We believe these results, particularly the safety data, underscore GRI-0621’s potential to provide a much needed safe and effective treatment option for the treatment of IPF, where there remains ...

A promising new treatment approach for idiopathic pulmonary fibrosis (IPF), a fatal and currently untreatable lung disease affecting over 3 million people globally, has been identified by Tulane ...

Munich, Germany – April 9, 2025-- Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced its ...

Shionogi and InterMune have announced the marketing approval of pirfenidone (Pirespa) for the treatment of idiopathic pulmonary fibrosis (IPF) in Japan, making it the first approved therapy for ...

Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.